On Thursday, Zuanic & Associates began coverage on InterCure Ltd. (NASDAQ: INCR) with an Overweight rating, highlighting the company's strong position as the leading seller of pharmaceutical cannabis (PHC) outside North America. The firm did not set a price target but suggested that a 5x return could be possible for InterCure due to several growth factors in the pharmaceutical cannabis market.
InterCure is poised to capitalize on recent regulatory changes in Israel, which could potentially triple demand. The company is also strategically positioned to penetrate key European markets, with Germany being a notable example where the market could expand significantly in the next three years. Zuanic & Associates emphasized InterCure's strategic value within the global industry, citing its expertise in Israeli PHC, ability to produce high-quality flower under stringent GMP standards, and a valuable bank of strains and genetics.
Despite challenges faced in the fourth quarter of 2023, when attacks disrupted production at InterCure's key southern facility leading to a sequential sales drop of more than 50%, the firm sees a bright future for the company. The strong demand that persisted despite the production setback, along with the stock's performance—having tripled since the October 7 bottom—supports the analyst's positive outlook.
Zuanic & Associates also noted that InterCure's potential entry into the U.S. market could be a game-changer if FDA-approved and federally legalized pharmaceutical cannabis becomes a reality. The firm believes that InterCure's international brand rights, including Cookies, add to its strategic value and reinforce its standing as the number one player in Israel's market, which is currently larger than Germany's.
InvestingPro Insights
Zuanic & Associates' optimistic coverage of InterCure Ltd. (NASDAQ: INCR) aligns with some key metrics from InvestingPro. The company's high shareholder yield is a strong indicator of its commitment to delivering value to its investors, even as analysts remain cautious about its profitability in the near term. Despite not being profitable over the last twelve months, InterCure has demonstrated a robust return over the past month, with a significant 19.23% increase, and an even more impressive three-month return of 64.02%. These figures, coupled with a 176.79% surge over the last six months, reflect a bullish trend for the company's stock.
However, the InvestingPro Data reveals some challenges, with a negative revenue growth of -8.52% over the last twelve months as of Q4 2023, and a quarterly revenue decline of -30.43% in Q4 2023. The company's EBITDA also fell sharply by -86.18% during the same period. Despite these figures, InterCure's market cap stands at $139.75M, and its price/book ratio as of Q4 2023 is at a moderate 1.13, which may appeal to value investors.
For those considering a deeper dive into InterCure's financial health and future prospects, InvestingPro provides additional insights. With the use of coupon code PRONEWS24, readers can access an even broader range of InvestingPro Tips, including 9 more tips, by visiting https://www.investing.com/pro/INCR. These tips can offer a more nuanced view of the company's financial landscape and help investors make informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.